Biopharma

increase
Biotech

Biopharma biobucks decline, while upfront deal payments rise

While the average earnout potential per biopharma deal has declined over the last six years, the mean upfront value has been on the rise since 2017.
Gabrielle Masson Sep 24, 2025 11:30am
workers

Fierce Biotech Layoff Tracker 2025: Heidelberg, Rome, & more

Sep 23, 2025 2:45pm
flat earth

FDA leadership 'decapitated,' former leader Janet Woodcock says

Apr 7, 2025 4:04pm